Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EEDVsMit in children with recurrent/refractory solid or CNS tumors
NCT02687386Phase 1Terminated
- Start
- Feb 2016
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EEDVsMit in solid tumor, central nervous system tumor and diffuse intrinsic pontine glioma (DIPG). Primary endpoints: Maximum Tolerated Dose at 28 days, Incidence of treatment-related adverse events and 1 more. Started Feb 2016; status: terminated.
02
Drugs
EEDVsMit
03
Conditions
solid tumorcentral nervous system tumordiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT02687386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02687386.